

Pancreatic Panniculitis: A Rare Manifestation of Pancreatic Disease

Rita Andrade^{1*}, Cristina P Camacho^{1,2}, António Canaveira Manso^{1,2} and Mário Sérgio^{1,2}

¹General Surgery Department, Coimbra University Hospital Centre, Coimbra, Portugal

²Faculty of Medicine, Coimbra University, Coimbra University, Coimbra, Portugal.

Received November 20, 2020; Revised December 14, 2020; Accepted January 23, 2021

ABSTRACT

Pancreatic panniculitis is a very rare complication associated with pancreatic disease, appearing in approximately 2 to 3% of all patients, most commonly those with acute or chronic pancreatitis, but also in patients with pancreatic carcinoma. Clinical manifestations include painful erythematous nodules, which usually develop on the lower limbs. The pathogenesis is not fully understood, but it seems that the release of high amounts of pancreatic enzymes may lead to a focal necrosis of lipids and a concomitant inflammatory reaction. The histological hallmark of pancreatic panniculitis is the presence of “ghost cells”. The treatment is mainly directed towards the underlying pancreatic disease, which may result in regression of skin lesions. This review of literature aims to present current knowledge on pancreatic panniculitis.

Keywords: Pancreatic Panniculitis, Pancreatic Fat Necrosis, Enzymatic Panniculitis, Ghost Cells

INTRODUCTION

Fist described in 1883 by Chiari [1], Pancreatic panniculitis (PP), also known as pancreatic fat necrosis and enzymatic panniculitis, is a rare necrosis of subcutaneous adipocytes triggered by inflammatory, traumatic or malignant pancreatic disease.

While rare, skin signs associated with pancreatic disease may lead to an early diagnosis or predict the severity of the underlying illness and clinicians should be aware of these cutaneous signs in pancreatic pathology in order to recognize them and appropriately direct management [2].

In the review, we discuss the clinical characteristics, treatment and prognostic value of the lesions.

EPIDEMIOLOGY AND ETIOLOGY

PP occurs in 2-3% of all patients with pancreatic disease [3]. PP is usually described in association with benign pancreatic conditions, such as acute or chronic pancreatitis. Acute pancreatitis is the most common cause of PP, mainly secondary to alcoholism, cholelithiasis, drugs or trauma [4-6]. It is less usually described in association with pancreatic carcinoma: usually of the acinar cell carcinoma (in 80% of cases), which represents 10% of pancreatic malignant tumours [5,7], although it has been reported in the course of some other carcinomas, such as ductal adenocarcinoma and neuroendocrine carcinoma [3].

Other less frequent pancreatic abnormalities that have been described in association with PP include pancreas divisum, pancreatic pseudocysts, vasculopancreatic fistulas and pancreatitis secondary to sulindac intake [3].

PP may present during pancreatic disorder or may be diagnosed before the underlying disease about 40% of the time [8]. Skin lesions may precede the detection of the pancreatic disease by about 1-7 months and in cases of malignancies, it may be associated with increased risk of metastasis and/or associated with disease severity [6,9].

PP is typically diagnosed in older patients. The median age at the diagnosis is 60 years, however, it can potentially appear at any age [4]. PP has a male predominance (M:F = 4:1) but this is most probably due to a higher prevalence of conditions like chronic pancreatitis in male patients and does not result from an impact of gender on pathogenesis [8].

Corresponding author: Rita Andrade, Centro Hospitalar e Universitário de Coimbra, Praceta Professor Mota Pinto, 3000-075, Coimbra, Portugal, Tel: + 351 239400400; E-mail: ritaandrade03@gmail.com

Citation: Andrade R, Camacho CP, Manso AC & Sérgio M. (2021) Pancreatic Panniculitis: A Rare Manifestation of Pancreatic Disease. *Int J Surg Invasive Procedures*, 4(2): 179-182.

Copyright: ©2021 Andrade R, Camacho CP, Manso AC & Sérgio M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PATHOPHYSIOLOGY

The exact pathophysiology of PP is poorly understood because detailed mechanistic studies are lacking and are not easy to perform in view of the rarity of the condition [4]. It is thought that the release of pancreatic enzymes (trypsin, lipase, amylase) in the bloodstream may be involved in increasing the vessel permeability with consequent neutral fat hydrolysis to form glycerol and free fatty acids, and finally producing fat necrosis and inflammatory response [2]. Lipase activity seems to be more relevant; this is supported by the numerous cases with normal amylase levels reported and by the finding that the necrotic tissue stains positive for lipase [10]. However, lipase levels are not the only factor implicated, as the relative frequency of pancreatitis with high serum lipase levels contrasts with the rarity of pancreatic panniculitis, and there are some PP cases in the literature that have been described with normal serum levels of all pancreatic enzymes [3], supporting the likely involvement of other unidentified factors in the causality of this entity. Immune complexes and release of inflammatory cytokines (especially adipokines) have also been proposed as possible pathogenic mechanisms [2]. Also, both skin and pancreatic inflammation share phospholipase A2 as a mediator, which could be targeted as with therapy in some inflammatory conditions [11].

DIAGNOSTIC PROCEDURES AND DIFFERENTIAL DIAGNOSIS

Clinically, PP usually presents with erythematous-violaceous plaques and painful nodules predominantly located on the lower limbs (around the ankles and pretibial region), but which can also affect other areas like upper extremities, chest or scalp [12]. These cutaneous lesions may resolve spontaneously or, in advanced cases, can ulcerate, draining an oily brown, sterile, viscous substance due to liquefactive fat necrosis (**Figure 1**) [3].



Figure 1. Subcutaneous erythematous nodule on the lower limbs.

It is important to differentiate PP from others forms of panniculitis. The differential diagnosis includes erythema nodosum, lupus panniculitis, panniculitides in sarcoidosis, and erythema induratum of Bazin/nodular vasculitis [8].

Laboratory tests usually show pancreatic hyperenzymemia, leucocytosis and an increase of acute phase reactants. Eosinophilia and leukemoid reactions have been described in patients with pancreatic carcinoma [5]. Imaging exams are used to detect the underlying pancreatic disease.

The appropriate diagnostic tool for evaluation of skin lesions is a biopsy for anatomopathological study. Histopathological examination shows a mostly lobular panniculitis without vasculitis. But, in the very early stage, a septal pattern has been described, which results from enzymatic destruction of the endothelial septa, allowing pancreatic enzymes to cross from blood to fat lobules resulting in coagulative necrosis of the adipocytes, which leads to pathognomonic "ghost cells". These cells are anucleate necrotic adipocytes that have a thick wall with a fine basophilic granular material within their cytoplasm from dystrophic calcification. This is a result of saponification of fat derived to the action of pancreatic enzymes in subcutaneous fat and followed by calcification. In older lesions, "ghost cells" and fat necrosis decreases, replaced by granulomatous inflammatory infiltrate composed of foamy histiocytes and multinucleated giant cells [3,13].

Arthritis occurs in 50-80% of PP cases as a result of necrosis of the periarticular adipocytes [5]. Some authors have also described the association between pancreatitis, panniculitis and polyarthritis, named PPP syndrome [14].

TREATMENT

Treatment of PP consists of identifying and addressing the underlying condition. Endoscopy or surgical therapy may be warranted, which normally leads to resolution of cutaneous lesions. Symptomatic relief with non-steroidal anti-inflammatory drugs is also recommended [15]. Some authors suggested that PP may also benefit from octreotide, a synthetic somatostatin-like polypeptide, which inhibits pancreatic enzyme production [16].

In the setting of pancreatic malignancy, resolution on PP has been reported with chemotherapy [17]. For oncologic therapy of ductal adenocarcinoma and neuroendocrine carcinoma, established treatment programs have been published in clinical guidelines [18,19]. For acinar cell carcinoma, which is a common cause of PP, systematic therapy studies are lacking. Whenever possible, complete resection should be intended [20]. However, this is often avoided by locally advanced tumor or metastatic spread already at diagnosis [21]. Chemotherapy protocols that have been used include FOLFOX, FOLFIRI, and FOLFIRINOX as well as gemcitabine-based regimens [17]. A recent review suggested that fluoropyrimidine-based chemotherapy might lead to a better outcome [21]. In unresectable cases without

distant metastasis, chemotherapy is usually combined with radiotherapy [22]. Other approaches that have been reported in the metastatic situation include palliative treatment of liver metastasis with trans arterial chemoembolization (TACE) or resection [23,24].

PROGNOSIS

Prognosis primarily depends on the underlying pancreatic disease and success in treating this condition. Concerning the skin manifestations, normalization of pancreatic enzyme levels subsequently leads to regression of panniculitis lesions in most cases [25,26]. Panniculitis seem to be a poor prognostic sign in malignant diseases. Patients with PP and underlying malignancy, on whom follow-up data was available, had a median overall survival of only 4 months. Even metastatic acinar cell carcinoma patients had a median overall survival of 17 months, while unresectable patients without metastasis and resectable patients survived 38 and 47 months, respectively [21].

DISCUSSION AND CONCLUSIONS

Pancreatic pathology mainly presents with gastrointestinal symptoms and signs. However, it can also associate a wide range of extra-digestive manifestations and cutaneous involvement plays an essential role both as a diagnostic clue for the pancreatic disease itself and serving as a prognostic factor for the gravity of the condition.

Although PP is rare, it is important to consider in the differential diagnosis of patients presenting with panniculitis. The skin manifestation can precede, occur simultaneously with or follow the pancreatic disease and PP should always prompt screening of an occult pancreatic malignancy.

The exact pathophysiology of PP is becoming clear but not entirely comprehended. The pathogenic role of pancreatic lipase is endorsed by the findings of the enzyme in the areas of subcutaneous necrosis and anti-lipase monoclonal antibodies within the necrotic tissue [13]. Pancreatic disorders are much more common when compared to PP which might indicate that there are still unrecognized factors involved in the development of pancreatic panniculitis.

The diagnosis of PP is suggested by the presence of pancreatic disease and clinical manifestations like ill-defined erythematous subcutaneous nodules more often localized in the lower extremities. Typical histopathological findings include subcutaneous lobular fat necrosis with a nuclear adipocyte called ghost cells.

The management of PP is primarily supportive and should be targeted to the underlying pancreatic disorder.

As more cases of PP are recognized and better characterized, the underlying mechanisms may also be better understood

perhaps leading to better vigilance to its incidence, causes, prognosis and treatment.

REFERENCES

- Chiari H (1883) Über die sogenanntefettnekrose. *Prag Med Wochenschr* 8: 255-256.
- Miulescu R, Balaban DV, Sandru F, Jinga M (2020) Cutaneous Manifestations in Pancreatic Diseases-A Review. *J Clin Med* 9: 2611.
- Requena L, SánchezYus E (2001) Panniculitis Part II. Mostly lobular panniculitis. *J Am Acad Dermatol* 45: 325-361.
- Zundler S, Strobel D, Manger B, Neurath MF, Wildner D, et al. (2017) Pancreatic Panniculitis and Polyarthritits. *Curr Rheumatol Rep* 19: 62.
- Sartorio CF, Combalia A, Ferrando J, Alsina M, Iranzo P, et al. (2018) Pancreatic panniculitis: A case series from a tertiary university hospital in Spain. *Australas J Dermatol* 59: e269-e272.
- Dunlop EJ, Takiguchi R, White CR Jr, White KP (2011) Fatal pancreatitis presenting as pancreatic panniculitis without enzyme elevation. *J Cutaneous Pathology* 38: 455-457.
- Moro M, Moletta L, Blandamura S, Sperti C (2011) Acinar cell carcinoma of the pancreas associated with subcutaneous panniculitis. *JOP* 12: 292-296.
- Guanziroli E, Colombo A, Coggi A, Gianotti R, Marzano AV, et al. (2018) Pancreatic panniculitis: the "bright" side of the moon in solid cancer patients. *BMC Gastroenterol* 18:1.
- Camacho CP, Santos E, Pimentão MB, Fraga AC, Simões JM, et al. (2020) Pancreaticpanniculitis: Case report. *Int Surg J* 7: 606-608.
- Zundler S, Erber R, Agaimy A, Hartmann A, Kiesewetter F, et al. (2016) Pancreatic panniculitis in a patient with pancreatic-type acinar cell carcinoma of the liver-case report and review of literature. *BMC Cancer* 16: 130.
- Dan P, Rosenblat G, Yedgar S (2012) Phospholipase A2 activities in skin physiology and pathology. *Eur J Pharmacol* 691: 1-8.
- Dahl PR, Su WP, Cullimore KC, Dicken CH (1995) Pancreatic panniculitis. *J Am Acad Dermatol* 33: 413-417.
- Laureano A, Mestre T, Ricardo L, Rodrigues AM, Cardoso J, et al. (2014) Pancreatic panniculitis-a cutaneous manifestation of acute pancreatitis. *J Dermatol Case Rep* 8: 35-37.

14. Graham PM, Altman DA, Gildenberg SR (2018) Panniculitis, pancreatitis, and polyarthritis: A rare clinical syndrome. *Cutis* 101: E34-E37.
15. Navarro IT, Ferrer NR, Estrada RB (2019) Pancreaticpanniculitis *Revista Espanola de Enfermedades Digestivas: Organó Oficial de la Sociedad Espanola de Patología Digestiva*. 111: 812-813.
16. Hudson-Peacock MJ, Regnard CF, Farr PM (1994) Liquefying panniculitis associated with acinous carcinoma of the pancreas responding to octreotide. *J R Soc Med* 8: 361-362.
17. Yoshihiro T, Nio K, Tsuchihashi K, Ariyama H, Kohashi K, et al. (2017) Pancreatic acinar cell carcinoma presenting with panniculitis, successfully treated with FOLFIRINOX: A case report. *Mol Clin Oncol* 6: 866-870.
18. Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, et al. (2015) ESMO Guidelines Committee. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 26: v56-v68.
19. Öberg K, Knigge U, Kwekkeboom D, Perren A (2012) ESMO Guidelines Working Group. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 23: vii124-vii30.
20. Kitagami H, Kondo S, Hirano S, Kawakami H, Egawa S, et al. (2007) Acinar cell carcinoma of the pancreas: clinical analysis of 115 patients from Pancreatic Cancer Registry of Japan Pancreas Society. *Pancreas* 35: 42-46.
21. Glazer ES, Neill KG, Frakes JM, Coppola D, Hodul PJ, et al. (2016) Systematic review and case series report of acinar cell carcinoma of the pancreas. *Cancer Control* 23: 446-454.
22. Seth AK, Argani P, Campbell KA, Cameron JL, Pawlik TM, et al. (2008) Acinar cell carcinoma of the pancreas: An institutional series of resected patients and review of the current literature. *J Gastrointest Surg* 12: 1061-1067.
23. Riediger C, Mayr M, Berger H, Becker K, Dobritz M, et al. (2012) Transarterial chemoembolization of liver metastases as symptomatic therapy of lipase hypersecretion syndrome. *J Clin Oncol* 30: e209-e212.
24. Banfill KE, Oliphant TJ, Prasad KR (2012) Resolution of pancreatic panniculitis following metastasectomy. *Clin Exp Dermatol* 37: 440-441.
25. Neves Z, Segura Ú, Valente A, Pacheco MH, Malhado J, et al. (2015) Panniculitis - A Rare Manifestation of Acute Pancreatitis. *GE Port J Gastroenterol* 22: 117-120.
26. Zhang G, Cao Z, Yang G, Wu W, Zhang T, et al. (2016) Pancreatic panniculitis associated with pancreatic carcinoma: A case report. *Medicine (Baltimore)* 95: e4374.